CA2066313C - Composition pharmaceutique - Google Patents

Composition pharmaceutique Download PDF

Info

Publication number
CA2066313C
CA2066313C CA 2066313 CA2066313A CA2066313C CA 2066313 C CA2066313 C CA 2066313C CA 2066313 CA2066313 CA 2066313 CA 2066313 A CA2066313 A CA 2066313A CA 2066313 C CA2066313 C CA 2066313C
Authority
CA
Canada
Prior art keywords
pharmaceutical composition
compositions
methyl
glioma
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA 2066313
Other languages
English (en)
Other versions
CA2066313A1 (fr
Inventor
Malcolm Francis Graham Stevens
Edward Stuart Newlands
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Campaign Technology Ltd
Original Assignee
Cancer Research Campaign Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/781,020 external-priority patent/US5260291A/en
Application filed by Cancer Research Campaign Technology Ltd filed Critical Cancer Research Campaign Technology Ltd
Publication of CA2066313A1 publication Critical patent/CA2066313A1/fr
Application granted granted Critical
Publication of CA2066313C publication Critical patent/CA2066313C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

CA 2066313 1991-10-18 1992-04-16 Composition pharmaceutique Expired - Lifetime CA2066313C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/781020 1991-10-18
US07/781,020 US5260291A (en) 1981-08-24 1991-10-18 Tetrazine derivatives

Publications (2)

Publication Number Publication Date
CA2066313A1 CA2066313A1 (fr) 1993-04-19
CA2066313C true CA2066313C (fr) 2002-08-20

Family

ID=25121424

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2066313 Expired - Lifetime CA2066313C (fr) 1991-10-18 1992-04-16 Composition pharmaceutique

Country Status (1)

Country Link
CA (1) CA2066313C (fr)

Also Published As

Publication number Publication date
CA2066313A1 (fr) 1993-04-19

Similar Documents

Publication Publication Date Title
EP0226266B1 (fr) Utilisation d'un dérivé du tétrahydrocarbazolone pour la fabrication de médicaments
US5985876A (en) Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
KR0148589B1 (ko) 항종양 효과의 상승 및 종양의 치료를 위한 조성물 및 키트
EP1104297B1 (fr) Compositions pour le traitement de la leucemie lymphocitaire chronique
US6403563B1 (en) Antitumor composition containing a synergistic combination of an anthracycline derivative with a camptothecin derivate
KR20010033028A (ko) 막-관련 바이러스 복제의 억제
US4980344A (en) Compositions for improving circulatory performance
PL198185B1 (pl) Zastosowanie Ekteinascydyny 743 do wytwarzania kompozycji farmaceutycznej
US4628047A (en) Agent for enhancing antitumor activity of antitumor agent
CA1326441C (fr) Compositions pharmaceutiques ayant une activite anti-cancereuse et methode de traitement du cancer
Burke et al. Imidazole carboxamide therapy in advanced malignant melanoma
EP0774255A1 (fr) Utilisation de l'acide ursolique pour la fabrication d'un médicament pour supprimer des métastases
CA2066313C (fr) Composition pharmaceutique
PL183644B1 (pl) Pochodne terpenoidowe (Sarcodictyiny) do stosowania jako środki przeciwnowotworowe i zwiększające łączenie się tubuliny, ich zastosowanie do wytwarzania leków oraz zawierające je kompozycje farmaceutyczne
KR100742524B1 (ko) 캄프토테신과 스틸벤 유도체를 포함하는 암 치료용 약제학적 병용제제
US5292497A (en) Method of reducing chemotherapy toxicity using (methylaminopropylamino)propyl dihydrogen phosphorothioate
CA2001004C (fr) Derives d'ergoline antivomitifs
EP0215200B1 (fr) Utilisation des sulfanilamido quinoxalines pour le traitement des maladies néoplastiques
EP0218453A1 (fr) Compositions et procédés anti-inflammatoires
EP0975338A2 (fr) Derives de 2,2'-bi-1h-pyrrole utilises pour traiter la leucemie provoquee par le virus htlv-1
US3456057A (en) Pharmaceutical compositions and methods utilizing 3-aminotricyclo(4.3.1.1**3.8)undecanes
EP0433682A2 (fr) Utilisation de 2,4,5-tri(4-méthoxyphényl)-4,5-dihydroimidazole pour le traitement du cancer
US20040138207A1 (en) Antitumor agents
JPH0513133B2 (fr)
EP0313094B1 (fr) Médicament anticancéreux et réactif pour l'obtention des revertants

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry
MKEX Expiry

Effective date: 20120416